Title	Publication Date	Language	Citations
Current knowledge on cannabinoids in oral fluid	2013/08/25	English	72
Voltammetric determination of isoproterenol using multiwall carbon nanotubes‐ionic liquid paste electrode	2011/02/09	English	71
The prevalence of new psychoactive substances in biological material – a three‐year review of casework in Poland	2015/12/14	English	71
An investigation of the stability of emerging new psychoactive substances	2013/11/04	English	70
Overview of regulation of dietary supplements in the USA and issues of adulteration with phenethylamines (PEAs)	2016/06/03	English	70
The first reported fatality associated with the synthetic opioid 3,4‐dichloro‐N‐[2‐(dimethylamino)cyclohexyl]‐N‐methylbenzamide (U‐47700) and implications for forensic analysis	2016/05/27	English	70
Prevalence of new psychoactive substances: A retrospective study in hair	2012/04/22	English	69
The emergence of new psychoactive substance (NPS) benzodiazepines: A review	2017/07/31	English	69
Recent advances in analytical methods for the therapeutic drug monitoring of immunosuppressive drugs	2017/09/28	English	69
Synthetic cannabimimetic agents metabolized by carboxylesterases	2014/10/24	English	69
Hypoxia‐inducible factor stabilizers and other small‐molecule erythropoiesis‐stimulating agents in current and preventive doping analysis	2012/02/24	English	67
Characterization of the designer benzodiazepine diclazepam and preliminary data on its metabolism and pharmacokinetics	2014/03/06	English	66
SARCOSYL‐PAGE: a new method for the detection of MIRCERA‐ and EPO‐doping in blood	2009/11/01	English	66
Cannabinoid disposition in oral fluid after controlled smoked, vaporized, and oral cannabis administration	2016/10/13	English	66
Detection of EPO doping and blood doping: the haematological module of the Athlete Biological Passport	2012/02/28	English	66
An overview of gamma‐hydroxybutyric acid: pharmacodynamics, pharmacokinetics, toxic effects, addiction, analytical methods, and interpretation of results	2011/03/04	English	66
Metabolism and disposition of N,N‐dimethyltryptamine and harmala alkaloids after oral administration of ayahuasca	2012/04/19	English	66
Detection of the recently emerged synthetic cannabinoid 5F–MDMB‐PICA in ‘legal high’ products and human urine samples	2017/05/24	English	65
Changes in the prevalence of new psychoactive substances before and after the introduction of the generic scheduling of synthetic cannabinoids in Japan	2013/12/26	English	65
Therapeutic mechanisms of classic hallucinogens in the treatment of addictions: from indirect evidence to testable hypotheses	2012/07/01	English	65
GHB and synthetic cathinones: clinical effects and potential consequences	2010/12/02	English	64
A brief history of ‘new psychoactive substances’	2011/07/01	English	64
The Drug Information and Monitoring System (DIMS) in the Netherlands: Implementation, results, and international comparison	2011/09/01	English	64
Detectability of designer benzodiazepines in CEDIA, EMIT II Plus, HEIA, and KIMS II immunochemical screening assays	2016/07/01	English	63
European guidelines for workplace drug and alcohol testing in hair	2016/07/12	English	63
Prevalence and co‐existence of active components of ‘legal highs’	2012/05/01	English	63
Dried blood spots: Concepts, present status, and future perspectives in bioanalysis	2014/04/01	English	63
Sensitive and fast identification of urinary human, synthetic and animal insulin by means of nano‐UPLC coupled with high‐resolution/high‐accuracy mass spectrometry	2009/05/01	English	62
A methamphetamine analog (N,α‐diethyl‐phenylethylamine) identified in a mainstream dietary supplement	2013/10/14	English	62
Acute intoxication by synthetic cannabinoids – Four case reports	2013/05/20	English	61